My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.1803 -0.0602 (-25.03%)

Official Closing Price Updated: 5:00 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 8 Next >

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

August 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

August 18, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

July 17, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Recap: Can Fite Biofarma Q1 Earnings ↗

June 01, 2023

Via Benzinga

Can-Fite to Present at the Emerging Growth Conference on July 13, 2023

July 07, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

June 29, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

June 13, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

June 02, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

June 01, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

May 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

May 15, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

May 09, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 05, 2023

Via Benzinga

Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

May 02, 2023

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 02, 2023

Via Benzinga

Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

May 02, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization

April 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 13, 2023

It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 11, 2023

Via Benzinga

Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

April 10, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know ↗

March 30, 2023

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months...

Via Benzinga

Can-Fite Reports 2022 Financial Results & Provides Clinical Update

March 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

March 16, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

March 13, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

February 14, 2023

During Tuesday, 40 stocks hit new 52-week lows.

Via Benzinga

Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo

February 14, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

February 10, 2023

During Friday, 48 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 25, 2023

On Wednesday, 22 companies hit new 52-week lows.

Via Benzinga

Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

January 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

January 11, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.